Liraglutide, a Glucagon-Like Peptide-1 Analog, Increased Insulin Sensitivity Assessed by Hyperinsulinemic-Euglycemic Clamp Examination in Patients with Uncontrolled Type 2 Diabetes Mellitus

Table 4

Correlation between changes in glucose infusion rate at euglycemic-hyperinsulinemic clamp and clinical variables in patients treated with liraglutide.

		value
Changes in body mass index	−0.086	0.760
Changes in hemoglobin A1c (%)	−0.101	0.710
Changes in fasting blood glucose (mg/dL)	−0.165	0.540
Changes in fasting blood insulin (µU/mL)	0.128	0.650
Changes in fasting blood CPR (ng/mL)	−0.154	0.583
Changes in postprandial blood glucose (mg/dL)	−0.383	0.143
Changes in postprandial blood insulin (µU/mL)	0.067	0.819
Changes in postprandial blood CPR (ng/mL)	−0.293	0.309

CPR: C-peptide radioimmunoreactivity.